Comparative study of alprenolol and methyldopa in previously untreated essential hypertension.

Vedin, J. A.; Wilhelmsson, Claes; Werkö, Lars

doi:10.1136/hrt.35.12.1285

Cited by 27 publications

(9 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, usually the patients had to start therapy again after drug-free periods of varying length because of a subsequent rise in BP. The carry-over effect of alprenolol has recently also been recorded by Vedin et al (13).…”

Section: Discussionsupporting

confidence: 55%

Long‐term Effect of Alprenolol as Antihypertensive Agent

Bengtsson

1974

Journal of Internal Medicine

View full text Add to dashboard Cite

Alprenolol was given to 26 women, participants in a population study, who were found to have arterial hypertension. These women were followed up for about two years, during which period they received β‐adrenergic blocking agents. Except for 6 weeks on placebo and 8 weeks on propranolol, alprenolol was given during the period. Those who had an initial effect from alprenolol also had long‐term benefit of the substance. Blood pressure seemed to remain at the same level during a follow‐up period of two years. Except for one woman who at the end of the two‐year period had slight obstructive bronchial symptoms, which may have been caused by alprenolol, no adverse reactions were seen. After an initial rise when starting treatment with alprenolol serum uric acid values were subsequently normalized and after a two‐year period they seemed to be even lower than the pre‐treatment values.

show abstract

Section: Discussionsupporting

confidence: 55%

Long‐term Effect of Alprenolol as Antihypertensive Agent

Bengtsson

1974

Journal of Internal Medicine

View full text Add to dashboard Cite

show abstract

“…This is a problem with many antihypertensive drugs, especially p-adrenergic blocking agents. 8 We have found with both propranolol and atenolol that blood pressure may take several weeks or even months to reach initial levels after treatment has stopped. So unless periods of treatment are very long a double-blind study without crossover is preferable.…”

Section: Discussionmentioning

confidence: 99%

Controlled study of atenolol in treatment of hypertension.

Hansson¹,

Åberg²,

Karlberg³

et al. 1975

BMJ

View full text Add to dashboard Cite

“…BP in the seated position at the last clinical visit on alprenolol, before switching over to metoprolol, and at the end of the placebo and metoprolol periods, respectively, is presented for each group (those who started on placebo and those who started on metoprolol) in (-) and metoprolol (---). 15). N o abnormal values were found for Hb, hematocrit, leucocytes, thrombocytes, serum bilirubin, alkaline phosphatases, SGOT or SGPT.…”

Section: Comparison Between Inetoprolol and Placebomentioning

confidence: 96%

The Effect of Metoprolol —a New Selective Adrenergic β₁‐receptor Blocking Agent—in Mild Hypertension

Bengtsson

1976

Journal of Internal Medicine

View full text Add to dashboard Cite

Metoprolol, a new selective adrenergic β1‐receptor blocking drug, has been compared to placebo in a series of 24 women who previously had taken alprenolol and propranolol during a cross‐over study. Blood pressure (BP) and heart rate (HR) were significantly reduced during metoprolol treatment compared to placebo. The occurrence of side‐effects was similar during treatment with metoprolol and placebo. After the cross‐over study the patients continued on metoprolol for more than two years, except for short periods on placebo or propranolol. During this follow‐up period BP remained at a similar level when the metoprolol dose was unchanged. Dose reduction (from SO or 100 mg t.i.d. to 50 or 100 mg b.i.d.) caused no, or only a very slight, increase in BP. No side‐effects were reported during long‐term treatment.

show abstract

Comparative study of alprenolol and methyldopa in previously untreated essential hypertension.

Abstract: The effects of methyldopa and alprenolol were compared in I5 patients with previously untreated essential hypertension. The patients were randonly allocated to start treatment with one of the drugs. All

Cited by 27 publications

References 22 publications

Long‐term Effect of Alprenolol as Antihypertensive Agent

Long‐term Effect of Alprenolol as Antihypertensive Agent

Controlled study of atenolol in treatment of hypertension.

The Effect of Metoprolol —a New Selective Adrenergic β₁‐receptor Blocking Agent—in Mild Hypertension

Contact Info

Product

Resources

About

Comparative study of alprenolol and methyldopa in previously untreated essential hypertension.

Abstract: The effects of methyldopa and alprenolol were compared in I5 patients with previously untreated essential hypertension. The patients were randonly allocated to start treatment with one of the drugs. All

Cited by 27 publications

References 22 publications

Long‐term Effect of Alprenolol as Antihypertensive Agent

Long‐term Effect of Alprenolol as Antihypertensive Agent

Controlled study of atenolol in treatment of hypertension.

The Effect of Metoprolol —a New Selective Adrenergic β1‐receptor Blocking Agent—in Mild Hypertension

Contact Info

Product

Resources

About

The Effect of Metoprolol —a New Selective Adrenergic β₁‐receptor Blocking Agent—in Mild Hypertension